These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 38308252)

  • 1. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ethnic minority status on tuberculosis diagnosis and treatment delays in Hunan Province, China.
    Gilmour B; Xu Z; Bai L; Alene KA; Clements ACA
    BMC Infect Dis; 2022 Jan; 22(1):90. PubMed ID: 35081919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study.
    Akalu TY; Clements ACA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):198. PubMed ID: 38350860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study.
    Htun YM; Khaing TMM; Yin Y; Myint Z; Aung ST; Hlaing TM; Soonthornworasiri N; Silachamroon U; Kasetjaroen Y; Kaewkungwal J
    BMC Health Serv Res; 2018 Nov; 18(1):878. PubMed ID: 30458776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
    Zheng XB; Diwan VK; Zhao Q; Hu Y; Bruchfeld J; Jiang WL; Hoffner S; Xu B
    Infect Dis Poverty; 2020 Jul; 9(1):97. PubMed ID: 32682446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.
    Liang L; Wu Q; Gao L; Hao Y; Liu C; Xie Y; Sun H; Yan X; Li F; Li H; Fang H; Ning N; Cui Y; Han L
    Thorax; 2012 Jul; 67(7):632-8. PubMed ID: 22403070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.
    Koroma JA; Elduma AH; Sesay U; Gebru GN
    BMC Infect Dis; 2024 Jun; 24(1):579. PubMed ID: 38862873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study.
    Kizito E; Musaazi J; Mutesasira K; Twinomugisha F; Namwanje H; Kiyemba T; Freitas Lopez DB; Nicholas NS; Nkolo A; Birabwa E; Dejene S; Zawedde-Muyanja S
    BMC Infect Dis; 2021 Mar; 21(1):292. PubMed ID: 33752637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013-2017.
    Okethwangu D; Birungi D; Biribawa C; Kwesiga B; Turyahabwe S; Ario AR; Zhu BP
    BMC Infect Dis; 2019 May; 19(1):387. PubMed ID: 31064332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.
    Iradukunda A; Ndayishimiye GP; Sinarinzi D; Odjidja EN; Ntakaburimvo N; Nshimirimana I; Izere C
    BMC Public Health; 2021 Nov; 21(1):2142. PubMed ID: 34814876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study.
    Elduma AH; Mansournia MA; Foroushani AR; Ali HMH; Elegail AMA; Elsony A; Holakouie-Naieni K
    Epidemiol Health; 2019; 41():e2019014. PubMed ID: 31010280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
    Ködmön C; van den Boom M; Zucs P; van der Werf MJ
    Euro Surveill; 2017 Nov; 22(47):. PubMed ID: 29183553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study.
    Hirpa S; Medhin G; Girma B; Melese M; Mekonen A; Suarez P; Ameni G
    BMC Public Health; 2013 Aug; 13():782. PubMed ID: 23981845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
    Alene KA; Viney K; McBryde ES; Gray DJ; Melku M; Clements ACA
    Transbound Emerg Dis; 2019 Jul; 66(4):1611-1618. PubMed ID: 30924283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.